Pune,  INDIA
New York, United States , Jan.  15, 2023  (GLOBE NEWSWIRE) -- The Global Erdosteine Market Size to grow from USD 120.00 million in 2021 to USD 228.14 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period. The rising population pool suffering from different respiratory disorders, such as chronic obstructive pulmonary diseases and bronchitis, is expected to raise demand for erdosteine dramatically. Asia Pacific is expected to grow the fastest during the forecast period. Global Economy: Recession Risk Rising Analysis and Russia-Ukraine Conflict War Impact we have added in the final premium report. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1412  
On credit portfolios, the COVID-121.9 epidemic has had a negative effect. The enormous growth has hampered the solvency of customers and business in unemployment and interruption of economic activity. Central banks have adopted a proactive strategy of injecting money into the market by decreasing interest rates and implementing asset purchase programmes. With persistent geopolitical tensions, global trade battles, and sporadic hurricanes and earthquakes, managing and monitoring credit, market, liquidity, and operational risk across financial markets was challenging enough. Chief risk officers and their teams have had to reevaluate outdated methods and assumptions used to manage and monitor risk due to the present pandemic crisis. The global repercussions of COVID-19 have demonstrated the significance of interconnection in international cooperation. As a result, many governments have been hurrying to find, assess, and buy trustworthy AI-powered solutions. Browse key industry insights spread across 191 pages with 106 market data tables and figures & charts from the report “ Global Erdosteine Market Size , Share, and COVID-19 Impact Analysis, By End-use (Pharmaceutical, CMOs and Research Institutes), By Application (Bronchitis, COPD, Nasopharyngitis and Others) and by Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Analysis and Forecast 2030.”, in detail along with the table of contents. Buy Now Full Report: https://www.sphericalinsights.com/checkout/1412  
The COPD segment to account for the largest market size during the forecast period. Based on the application, the erdosteine market is categorized into Bronchitis, COPD, Nasopharyngitis and Others. The COPD segment to account for the largest market size during the forecast period. Throughout the forecast period, the COPD segment is anticipated to maintain its leading position. The incidence of COPD is anticipated to increase throughout the projection period due to an important increase in the ageing populations in several nations, including Japan, Italy, and Greece, as well as the rising prevalence of smoking. Along with its propensity to worsen with time, COPD is a significant, life-threatening condition, which should propel the expansion of the erdosteine market share. Significant COPD risk factors include women's increasing acceptance of tobacco use, particularly in high-income countries like the UK, Switzerland, and Norway. Regional Segment Analysis of the Erdosteine Market
North America (U.S., Canada, Mexico) 
Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
Asia-Pacific (China, Japan, India, Rest of APAC)
South America (Brazil and the Rest of South America) 
The Middle East and Africa (UAE, South Africa, Rest of MEA)
Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/1412  
The Pharmaceutical segment to hold a higher CAGR during the forecast period. Based on the end-use, the erdosteine market is categorized Pharmaceutical, CMOs and Research Institutes. The Pharmaceutical segment to hold a higher CAGR during the forecast period. Throughout the forecast period, the pharmaceutical segment is anticipated to maintain its leading position while expanding at the fastest CAGR this is a result as Market share should be enhanced by escalating technological progress, an ageing population, and rising pharmaceutical company R&D investment. erdosteine market growth should be accelerated by rising consumer desire for preventative healthcare, particularly with the arrival of the COVID-19 pandemic which increased the need for respiratory medications. North America is estimated to account for the highest market share in 2022. The global erdosteine market has been segmented into five major regions:  North America, Europe, Asia-Pacific, South America, The Middle East and Africa. The rising acceptance by the market are driving the demand for erdosteine. The North America region dominated the market for erdosteine this is explained as smoking, drug use, and alcohol use have increased, North America has seen a marked rise in mental health issues such as anxiety, restlessness, and suicidal thoughts, especially among young adults. E-cigarette adoption in the area should be sparked by the low perceived danger of e-cigarettes, enticing flavours, and growing young interest, which is anticipated to increase the prevalence of COPD and enhance the erdosteine market share. Asia Pacific to hold a higher CAGR during the forecast period. Get Discount At @ https://www.sphericalinsights.com/request-discount/1412  
Competitive Landscape
The report offers the appropriate analysis of the key organizations/companies involved within the global Complex Inorganic Color Pigments Market along with a comparative evaluation primarily based on their Product offering, business overviews, geographic presence, enterprise strategies, segment Market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including Product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the Market. Companies Covered: Reine Lifescience, Recipharm, Delta Finochem Pvt.Ltd., Berchemia Healthcare, Angelini Fine Chemicals, Edmond Pharma, Alitair Pharmaceuticals, Zhejiang Kangle Pharmaceutical, Wuhan Yuancheng Pharmaceutical, and Shanghai Pukang Pharmaceuticals. View a Detailed Table Of Content Here: https://www.sphericalinsights.com/table-of-contents/erdosteine-market  
Browse Related Reports:
Global Povidone Iodine Market Size, Share, and COVID-19 Impact Analysis, By Formulation Type (Scrub, Topical Solution, and Ointments), by Concentration (10% Solution and 7.5% Solution), By Application (Instrument Sterilization, Skin Sterilization, and Disinfectant), and by Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030.

Global Erdosteine Market Size to grow USD 228.14 Million by 2030 | CAGR of 7.4%

Search jobs
14-Mar-2022
Nasal Antihistamines Market 2021 Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth
According to a recent study by Future Market Insights (FMI), the  nasal antihistamines market  is expected to witness steady growth during the forecast period. The market valuation is expected to increase from US$ 1.89 Bn in 2020 to over US$ 3.08 Bn by 2031. This reflects a cumulative CAGR of around 3.1% over the forecast period (2021-2031). Antihistamines are a class of medications that are often used to treat allergy symptoms. These medications are used to treat problems caused by an excess of histamine, a substance produced by the immune system. People who are allergic to pollen and other allergens are the most prevalent users of antihistamines. Sneezing, congestion, and itchy, runny nose can all be relieved with antihistamine sprays. They are available by prescription and include azelastine (Astelin, Astepro) and olopatadine (Patanase). The global burden of respiratory diseases such as allergic rhinitis, chronic obstructive pulmonary disease, asthma has increased rapidly in the last three decades. In an article published in NCBI, it was reported that around 20–30 % of the Indian population suffers from allergic rhinitis and that 15 % develop asthma. To remain ‘ahead’ of your competitors, request for a sample @  https://www.futuremarketinsights.com/reports/sample/REP-GB-13708
Due to this growing burden, there has been an increased adoption rate of nasal antihistamines in the form of nasal sprays and nasal drops, globally. The nasal antihistamines provide rapid and effective relief from the symptoms of allergic rhinitis. Thus, the growing number of allergic rhinitis cases will propel the growth of the nasal antihistamines market in the future. Advancements in the field of nasal drug delivery have enabled the establishment of several non-invasive approaches for treatment. Various new products such as metered dose delivery systems, innovative odorless powders and sprays, preservative-free nasal sprays and others are key drivers that will expand this industry in the forecast period. FDA approvals of various nasal sprays to switch from prescription to OTC use has led to increased independence concerning self-administration of drugs, amongst patients who suffer from allergic rhinitis. Various additions by the manufacturers to the already available product lines, especially for AR are some of the techniques used by the manufacturers to increase product penetration amongst the population. New product launches & approvals have emerged as key growth strategies adopted by the leading players in the nasal antihistamines market. Followed by this, the acquisition was the second most key strategy adopted by the industry players. By adopting these strategies, it helped the company to expand their regional presence as well as product offerings. For instance, In December 2020, GlaxoSmithKline launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerine as a product for the symptomatic relief of allergic rhinitis. Such developments not only strengthens the company’s existing portfolio but also help to increase their presence at the regional as well as global level, and helps companies to sustain the increasing competitive pressure. Some of the leading manufacturers of the nasal antihistamines market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence. The key market players covered by FMI include Bayer Healthcare LLC, Novartis International AG, Cipla, Glenmark Pharmaceuticals, GlaxoSmithKline, Sun Pharmaceuticals, Merck & Co., Centaur Pharmaceuticals, Viatris (Meda Pharmaceuticals), Proctor & Gamble, Ascend Laboratories LLC (Alkem Laboratories), J Pharmaceuticals, Alitair Pharmaceuticals and Sato Pharmaceuticals. For critical insights, request for PDF Brochure @  https://www.futuremarketinsights.com/reports/brochure/rep-gb-13708
Why Future Market Insights? • Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Us:

Nasal Antihistamines Market 2021 Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth

September 10, 2020 10:03 AM Eastern Daylight Time
This latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Bronchiectasis (Respiratory) pipeline landscape. Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents. Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 6 and 2 respectively. Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Key Topics Covered:
Bronchiectasis - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Bronchiectasis - Drug Profiles
Featured News & Press Releases
Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007
Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA
Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis
Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product
Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
Appendix
Zambon Co SpA

H1 2020 Bronchiectasis Pipeline Review - ResearchAndMarkets.com

16:14 EDT 3 Aug 2018 | BioPortfolio Reports
Summary
Alitair Pharmaceuticals Inc Alitair is a pharmaceutical company that offers orphan drugs and medicine products. The company offers orphan drug products and RX and OTC cough and cold products. Its orphan drug products comprise ALT and oral drugs that are widely used to treat various respiratory diseases but which we intend to develop for several orphan respiratory indications and also used in greater compliance and adherence for other inhaled drugs. The company markets its products in the US and abroad. Alitair is headquartered in Morristown, New Jersey, the US. Alitair Pharmaceuticals Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Alitair Pharmaceuticals Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile Report Updated 12042018 Prices from USD $250

Alitair to sell two ion-exchange resin patents
US-based Alitair Pharmaceuticals has retained Finn, Warnke & Gayton to sell two Alitair patents and an associated royalty stream at a sealed bid sale on 24 May 2013. The first patent, which was issued in 2012, covers the use of ion exchange resins in immediate-release and extended-release oral dosage forms. Issued in 2013, the second patent covers the use of ion exchange resins in immediate-release and extended-release oral formulations of benzonatate, a non-narcotic prescription cough product. The royalty stream includes milestone payments and has an estimated net present value of $7.5m. Either of the patents or both along with the royalty stream will be sold at the sealed bid sale, according to Alitair. Share:

Alitair to sell two ion-exchange resin patents

EMD Serono

Elan

Sanofi

Alitair Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary formulations for respiratory diseases. The company offers non-narcotic prescription cough medicines, ion exchange resin formulations, and a pipeline of Orphan Drugs designed to address unmet medical needs in the treatment of respiratory conditions. Alitair's business strategy includes internal product development, out-licensing of its overdose reduction technology, and forming strategic partnerships to enhance its product portfolio and therapeutic areas. It is based in Morristown, New Jersey.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
11/13/2020	Unattributed - IV	$0.04M	Undisclosed Investors	$XXM	0 FY undefined	1
10/9/2018	Unattributed - III	$XXM	Subscribe to see more	$XXM	0 FY undefined	10
3/10/2017	Unattributed - II	$XXM	Subscribe to see more	$XXM	0 FY undefined	10
9/30/2015	Unattributed	$XXM	Subscribe to see more	$XXM	$1M - $5M FY 2015	10

Date	11/13/2020	10/9/2018	3/10/2017	9/30/2015
Round	Unattributed - IV	Unattributed - III	Unattributed - II	Unattributed
Amount	$0.04M	$XXM	$XXM	$XXM
Investors	Undisclosed Investors	Subscribe to see more	Subscribe to see more	Subscribe to see more
Valuation	$XXM	$XXM	$XXM	$XXM
Revenue	0 FY undefined	0 FY undefined	0 FY undefined	$1M - $5M FY 2015
Sources	1	10	10	10

How VCs Use CB Insights

Professional Services

Platform Overview

Alitair Pharmaceuticals

Total Raised

Funding, Valuation & Revenue